Welcome to our dedicated page for Oruka Therapeutics news (Ticker: ORKA), a resource for investors and traders seeking the latest updates and insights on Oruka Therapeutics stock.
Oruka Therapeutics Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company pioneering novel antibody therapies for chronic inflammatory diseases. This page serves as the definitive source for verified corporate announcements, research developments, and regulatory updates.
Investors and industry observers will find timely updates on clinical trial progress, including updates for ORKA-001 (targeting IL-23p19) and ORKA-002 (inhibiting IL-17A/F). Our news feed covers material events from preclinical breakthroughs to partnership agreements, all processed through strict editorial verification.
The repository includes press releases on therapeutic advancements, financial filings, leadership updates, and scientific presentations. Each entry maintains neutral reporting standards while emphasizing Oruka's focus on extended-duration therapies through proprietary half-life extension technology.
Bookmark this page for streamlined access to Oruka's latest milestones in dermatology and immunology. For comprehensive tracking of this innovative biotech's progress, consider subscribing to our regulatory updates alert system.
Oruka Therapeutics (ORKA) has revealed promising preclinical data for ORKA-002, their novel extended half-life monoclonal antibody targeting IL-17A/F, at the 2025 AAD Annual Meeting. The drug demonstrated a remarkable half-life of over 30 days in non-human primates - more than triple that of bimekizumab.
Key findings show that ORKA-002 could potentially enable dosing intervals of once every four months to twice yearly in humans, based on projected pharmacokinetics. The drug exhibits equivalent potency and similar binding affinity to bimekizumab, binding IL-17A and IL-17F with comparable picomolar affinity.
The company plans to dose the first subject with ORKA-002 in Q3 2025. The drug is being developed for treating chronic skin diseases, including plaque psoriasis and psoriatic arthritis.
Oruka Therapeutics (ORKA) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical pipeline. The company's lead candidate ORKA-001, a novel IL-23p19 antibody, entered Phase 1 trials in December 2024, with PK data expected in 2H 2025 and Phase 2a initiation planned for 2H 2025.
Financial highlights include raising over $475 million in 2024 and ending the year with $393.7 million in cash and equivalents, providing runway through 2027. Q4 2024 showed R&D expenses of $25.5 million and G&A expenses of $4.8 million, with a net loss of $25.8 million.
The company's second candidate, ORKA-002, targeting IL-17A/F, is advancing with Phase 1 initiation expected in Q3 2025. Preclinical data will be presented at the 2025 AAD Annual Meeting. Additionally, Oruka disclosed ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001, and plans to reveal details about ORKA-003 in 1H 2025.
Oruka Therapeutics (Nasdaq: ORKA), a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in two major investor conferences in March 2025.
The company will present at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4th, 2025, at 10:30 AM ET, and at the Leerink Global Healthcare Conference on Wednesday, March 12th, 2025, at 8:40 AM ET.
Investors can access the webcasts and replays of these presentations through Oruka's investor events website at https://ir.orukatx.com/news-events/events-presentations.
Oruka Therapeutics (ORKA) has begun dosing healthy volunteers in its Phase 1 trial of ORKA-001, a novel half-life extended monoclonal antibody targeting IL-23p19 for treating chronic skin diseases. The trial will evaluate safety, tolerability, and pharmacokinetics in approximately 24 healthy volunteers across three subcutaneous dose cohorts.
Initial data is expected in H2 2025, followed by a proof-of-concept study in moderate-to-severe psoriasis. The subsequent study will involve about 80 subjects testing six-month and potential yearly dosing schedules, with initial efficacy data anticipated in H2 2026.
Preclinical data suggests potential for once- or twice-yearly dosing, representing a significant improvement over current standards. The company has also secured a worldwide exclusive license agreement with Paragon Therapeutics for ORKA-001 in all indications except inflammatory bowel disease.
Oruka Therapeutics (Nasdaq: ORKA), a biotechnology company focused on developing novel biologics for chronic skin diseases treatment, has announced its upcoming addition to the Nasdaq Biotechnology Index (NBI). The inclusion will be effective before market open on December 23rd, 2024. This addition reflects Oruka's meeting of specific eligibility criteria, including minimum market capitalization requirements, average daily trading volume thresholds, and public company seasoning period. The NBI tracks performance of biotechnology and pharmaceutical companies listed on Nasdaq, using a modified capitalization-weighted methodology with annual evaluation in December.
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its upcoming participation at Piper Sandler's 36th Annual Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, December 3rd, 2024, at 3:00 PM ET.
Oruka Therapeutics (Nasdaq: ORKA) reported Q3 2024 financial results and corporate updates. The company raised over $475 million through two transactions and completed its public listing on Nasdaq. Key highlights include accelerated clinical timelines for ORKA-001 and ORKA-002, with Phase 1 trials planned for Q1 2025 and Q3 2025 respectively. Financial results show $410.9 million in cash and equivalents, with a net loss of $28.6 million. R&D expenses totaled $25.7 million, while G&A expenses were $3.8 million. The company expects its current cash position to provide runway through 2027.
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in two major investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference on November 18th at 2:25PM ET and the Jefferies London Healthcare Conference on November 20th at 2:00PM GMT. Webcasts and replays of the presentations will be accessible through Oruka's investor events website.
Oruka Therapeutics (Nasdaq: ORKA) announced preclinical data for ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, at the European Academy of Dermatology and Venereology Congress. Key findings include:
1. Non-human primate (NHP) half-life of 30.3 days (subcutaneous) and 33.8 days (intravenous), over three times longer than risankizumab.
2. Projected human half-life of ~50 days could enable dosing every six months; ~75 days could allow yearly dosing.
3. Binds to a similar epitope with comparable affinity to risankizumab (below 5 picomolar).
4. Equivalent potency across various in vitro assays.
The extended half-life could result in higher antibody exposures, potentially leading to greater efficacy in treating chronic skin diseases like plaque psoriasis.
Oruka Therapeutics (Nasdaq: ORKA) has announced a $200 million private placement financing. The biotechnology company, focused on developing novel biologics for chronic skin diseases, is selling 5,600,000 shares of common stock at $23.00 per share, 2,439 shares of Series A non-voting convertible preferred stock at $23,000 per share, and pre-funded warrants for 680,000 shares at $22.999 per warrant. The PIPE financing includes participation from both new and existing investors, including major investment firms. Upon closing, Oruka will have approximately 55.1 million shares of common stock and equivalents outstanding. The company plans to use the proceeds for research and development, general corporate expenses, and working capital, expecting to fund its operating plan through 2027.
